Effects Of Pioglitazone Hydrochloride On The Concentrations Of Serum HsCRP And Plasm PAI-1 In The Patients After PCI

Background It will be faced that after Percutaneous coronary intervention(PCI) in-stent restenosis may happen.In clinic drug-eluting stent(DES) and medicine are widely used.DES can degrade the rate of restenosis to 5%～10%,but it make endodermis heal up put-off and thrombosis at a specified future date.Low-dose medicine lead to the low concentrations of pathological changes,which results in no ideal in guarding against restenosis.Preventing from in-stent restenosis shoud be strengthen.It has been discovered that more than 80%of the patients who have restenosis after Percutaneous coronary intervention(PCI) are accompanied by 2 type of diabetes(T2DM),the rate of restenosis of the patients with T2DM is twice as much as the patients withnot T2DM.It is deeded that preventing from in-stent restenosis in the patients with T2DM after PCI.Fibrinolysi and inflammation are very important to restenosis.C-reactive protein(CRP) and plasminogen activators inhibitor- 1(PAI-1) are usually used in fibrinolysi and inflammation.The concentrations of CRP and PAI-1 can forecast the rate of restenosis:the more,the higher.Can Pioglitazone Hydrochloride reduce restenosis after PCI? Rosiglitazone can.In fremdness,it has been reported that Pioglitazone Hydrochloride can reduce restenosis after PCI and in domestic rarely.In this text the restraining function of Pioglitazone Hydrochloride from CRP and PAI-1 were observed and the preventive function from reducing restenosis would be conferred,which could offer a theoretics gist for more investigating reducing restenosis of PioglitazoneMethods Twenty patients after PCI with ACS and T2DM were randomly devided into test group(n=10,treated with Pioglitazone Hydrochloride) and control group(n=10).The concentrations of PAI-1 in plasm,high sensitivity CRP(hs-CRP),total cholesterol(TC), triglyceride(TG),low density lipoprotein cholesterol(LDL-C)and high density lipoprotein cholesterol(HDL-C) in the blood serum,systolic blood pressure(SBP),diastolic blood pressure (DBP) and HbA1c in the blood serum were measured before and 1 month and 3 monthes after taking the medicine respectively.The major adverse cardiovascular events(MACE)were evaluated in 3 month after PCI.Result①The concentrations of hsCRP,TC,TG,LDL-C in the blood and SBP were similarly decreased while HDL-C increased in both groups after PCI.The concentrations of PAI-1,HbA_lc in blood and DBP were more evidently decreased in test group than in contron group.Pioglitazone Hydrochloride did interact with HbA1c in test group and not in contron group.②MACE had not happened in both groups. Conclusion Pioglitazone Hydrochloride which dose is 15mg a day for 3 monthes for the patients with ACS and T2DM after PCI will result in:①reducing blood glucose clearly.②no distinct influence to the concentrations of PAI-1 and hsCRP,in theory,without likelihood to reducing the restenosis for Pioglitazone that could degrade the concentrations of PAI-1 and hsCRP in blood.③no distinct influence to blood glucose and serum lipid.④security.